Enzyme Environmental Solutions, Inc.
Business Disclosure Statement

Part A General Company Information

Item I: The exact name of the issuer and its predecessor

Enzyme Environmental Solutions, Inc.

Formerly=Cucos Inc. until 3-2008
Security Notes
New Issue=12-83 600,000 shs at $5.00 by Howard, Weil, Labouisse, Friedrichs, Inc.

Item II: The address of the issuer’s principal executive offices

Jared Hockstedler
Enzyme Environmental Solutions, Inc.
6020 Huguenard
Fort Wayne, IN 46818
Phone: 260-399-3837Fax: 260-399-6354
http://www.enzymeenvironmentalsolutions.com/index.html

Item III: The jurisdiction(s) and date of the issuer’s incorporation or organization

03-18-1981 incorporated in State of Louisiana
02-26-2008 changed to Nevada

Item IV: The name and address of the transfer agent

PacWest Transfer, LLC
2510 Pines Road North Suite 206B
Spokane Valley, WA 99206
Tel: (509) 926-2330
Fax: (509) 926-2513
www.yourtransferagent.com

Item V: The nature of the issuer’s business

A. Business Development. Describe the development of the issuer and material events during the last three years so that a potential investor can clearly understand the history and development of the business. If the issuer has not been in business for three years, provide this information for any predecessor company. This business development description must also include:

1. The form of organization of the issuer (e.g., corporation, partnership, limited liability company, etc.);

Enzyme Environmental Solutions, Inc. is a Nevada corporation that was incorporated on 2-26-2008.
2. The year that the issuer (or any predecessor) was organized;

The issuer was organized in 1981 in the state of Louisiana.

3. The issuer’s fiscal year end date;

The fiscal end date of the company is 12-31.

4. Whether the issuer (or any predecessor) has been in bankruptcy, receivership or any similar proceeding;

The company has not been in bankruptcy.

5. Any material reclassification, merger, consolidation, or purchase or sale of a significant amount of assets;

There has been no material reclassification, merger, consolidation, or purchase or sale of a significant amount of assets.

6. Any default of the terms of any note, loan, lease, or other indebtedness or financing arrangement requiring the issuer to make payments;

There has been no default of the terms of any note, loan, lease, or other indebtedness or financing arrangement requiring the issuer to make payments.

7. Any change of control;

Persons who are or were affiliated with company, and estimated dates of affiliation:

2007-12-28 to Present Jared Hochstedler

Prior to 2007-12-21 Belmont Partners

8. Any increase of 10% or more of the same class of outstanding equity securities;

There has been an increase of 10% or more since change of control in December 28, 2007. A total of 220,000,000 common shares have been issued.

9. Any past, pending or anticipated stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization;

Reverse Split History

None

10. Any delisting of the issuer’s securities by any securities exchange or deletion from the OTC Bulletin Board.
There has been no delisting of the issuer’s securities by any securities exchange or deletion from the OTC Bulletin Board.

11. Any current, past, pending or threatened legal proceedings or administrative actions either by or against the issuer that could have a material effect on the issuer’s business, financial condition, or operations and any current, past or pending trading suspensions by a securities regulator. State the names of the principal parties, the nature and current status of the matters, and the amounts involved.

There are no pending legal proceedings against the issuer that will have a material effect on the issuer’s business, financial condition or operations. There are no current, past or pending trading suspensions.

B. **Business of Issuer.** Describe the issuer’s business so a potential investor can clearly understand it. To the extent material to an understanding of the issuer, please also include the following:

1. The issuer’s primary and secondary SIC Codes;

2890

2. If the issuer has never conducted operations, is in the development stage, or is currently conducting operations;

The issuer is currently in the development stage.

3. If the issuer is considered a “shell company” pursuant to Securities Act Rule 405;

Pursuant to the Securities Act Rule 405, the issuer is not considered a shell company.

4. The names of any parent, subsidiary, or affiliate of the issuer, and its business purpose, its method of operation, its ownership, and whether it is included in the financial statements attached to this disclosure statement;

There is no parent, subsidiary, or affiliate of the issuer.

5. The effect of existing or probable governmental regulations on the business;

There is no effect of existing or probable governmental regulations on the business.

6. An estimate of the amount spent during each of the last two fiscal years on research and development activities, and, if applicable, the extent to which the cost of such activities are borne directly by customers;

There has been no amount spent during each of the last two fiscal years on research and development activities, and, if applicable, the extent to which the cost of such activities are borne directly by customers.

7. Costs and effects of compliance with environmental laws (federal, state and local); and

There are no costs and effects of compliance with environmental laws.
8. The number of total employees and number of full-time employees;

There are a total of 7 fulltime employees.

**Item VI The nature of products or services offered**
In responding to this item, please describe the following so that a potential investor can clearly understand the products and services of the issuer:

A. Principal products or services, and their markets;

   Enzyme Environmental Solutions, Incorporated produces a unique multi-enzyme solution used in a wide variety of special purpose products. The Company manufactures the enzyme products solution based on its proprietary formulas. The primary markets for the Company’s products include: Retail, Agricultural, and Industrial. Enzyme use is standard in many industries such as cleaning, health, and manufacturing and as dietary supplements for both humans and animals. Enzymes act as a catalyst to accelerate the naturally occurring processes within nature. Enzyme Environmental Solutions uses no chemicals or hazardous materials to manufacture these enzymes, as all ingredients are environmentally friendly. The enzyme solution can be used to eliminate odor and organic matter - including blood stains - to clean carpets and counter tops, remove wall paper, and as a cleaner/degreaser. The wide breadth of products provided is the result of extensive research and development efforts. Over the last several years, the Company has expanded its product offering from four primary products to thirty-six distinct products. The Company continues to be focused on new markets and new product offerings.

B. Distribution methods of the products or services;

   All distribution methods of the products and services will be done by bulk shipping

C. Status of any publicly announced new product or service;

   All publicly announced new products and services have and will continue to be announced by press release.

D. Competitive business conditions, the issuer’s competitive position in the industry, and methods of competition;

   There are many competitive businesses within the industry.

E. Sources and availability of raw materials and the names of principal suppliers;

   The issuer does not have a principal supplier of raw materials.

F. Dependence on one or a few major customers;

   The company does not have a dependency on one or a few major customers.
G. Patents, trademarks, licenses, franchises, concessions, royalty agreements or labor contracts, including their duration; and

There are no Patents, trademarks, licenses, franchises, concessions, royalty agreements or labor contracts.

H. The need for any government approval of principal products or services and the status of any requested government approvals.

There is no need for any government approval of principal products or services and the status of any requested government approvals.

Item VII The nature and extent of the issuer’s facilities

6020 Huguenard Road, Fort Wayne, Indiana 46818

Part B Share Structure and Issuance History

Item VIII The exact title and class of securities outstanding

EESO As of 5-6-08

Common Stock 1 Billion authorized 223,716,508 outstanding 125,000,000 issuance pending

Cusip: 294113105

Preferred Stock

Class A 10 million authorize None outstanding

Class B 10 million authorized 1 million outstanding

Item IX: Description of the security

A. Par or Stated Value. Provide the par or stated value for each class of outstanding securities.

The par value for common and preferred stock is 0.001.

B. Common or Preferred Stock.
1. For common equity, describe any dividend, voting and preemption rights.

For common equity, there are no dividend, voting and preemption rights.

2. For preferred stock, describe the dividend, voting, conversion and liquidation rights as well as redemption or sinking fund provisions.

The preferred stock A is convertible with no voting rights and the preferred stock B is convertible with voting rights.

3. Describe any other material rights of common or preferred stockholders.

There are no material rights of common or preferred stockholders.

4. Describe any provision in issuer’s charter or by-laws that would delay, defer or prevent a change in control of the issuer.

There is no provision in issuer’s charter or by-laws that would delay, defer or prevent a change in control of the issuer.

**Item X** The number of shares or total amount of the securities outstanding for each class of securities authorized

In answering this item, provide the information below for each class of securities authorized. Please provide this information (i) as of the end of the issuer’s most recent fiscal quarter and (ii) as of the end of the issuer’s last two fiscal years.

Per PacWest on 12-31-2007 there was 2,605,397 common shares issued and outstanding.

The number of outstanding shares did not changed from 2005 through 2007.

(i) Period end date; 12-31-06

NA

(i) Period end date; 12-31-05

N/A

**Item XI:** List of securities offerings and shares issued for services in the past two years

No shares have been issued for services since 12-28-07. No knowledge of any shares issued for services prior to 12-28-07.

**Part C Management and Control Structure**

**Item XII:** The name of the chief executive officer, members of the board of directors, as well as control persons
A. Officers and Directors.

1. Full name;

Jared Hochstedler is the chief executive officer, sole director and officer.

2. Business address;

6020 Huguenard Road, Fort Wayne, Indiana 46818

3. Employment history (which must list all previous employers for the past 5 years, positions held, responsibilities and employment dates);

Enzyme Consultants, Inc, CEO 2001 to present

4. Board memberships and other affiliations;

There are no board members.

5. Compensation by the issuer; and

There is no compensation agreement.

6. Number and class of the issuer’s securities beneficially owned by each such person.

No shares are owned.

B. Legal/Disciplinary History

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

The issuer has not had a conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding.

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person’s involvement in any type of business, securities, commodities, or banking activities;
The insurer has not had an entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person’s involvement in any type of business, securities, commodities, or banking activities.

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or

The issuer has not been found by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated.

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred suspended or otherwise limited such person’s involvement in any type of business or securities activities.

The issuer has not been the subject of an order by a self-regulatory organization that permanently or temporarily barred, suspended or otherwise limited such person’s involvement in any type of business or securities activities.

C. Disclosure of Certain Relationships Describe any relationships existing among and between the issuer’s officers, directors and shareholders.

There are no relationships existing among and between the issuer’s officers, directors and shareholders.

D. Disclosure of Conflicts of Interest Describe any related party transactions or conflicts of interests. Provide a description of the circumstances, parties involved and mitigating factors for any related party transactions or executive officer or director with competing professional or personal interests.

There are no related party transactions or conflicts of interest.

Item XIII Beneficial Owners

Provide a list of the name, address and shareholdings of all persons beneficially owning more than five percent (5%) of any class of the issuer’s equity securities. To the extent not otherwise disclosed, if any of the above shareholders are corporate shareholders, provide the name and address of the person(s) owning or controlling such corporate shareholders and the resident agents of the corporate shareholders.

Jared Hochstedler

Item XIV: The name, address, telephone number, and email address of each of the following outside providers that advise the issuer on matters relating to the operations, business development and disclosure:

1. Investment Banker

The issuer has not retained an investor banker.
2. Promoters

The issuer has not hired promoters.

3. Counsel

The issuer has not retained counsel, however is in the process of doing so.

4. Accountant or Auditor - the information shall clearly (i) describe if an outside accountant provides audit or review services, (ii) state the work done by the outside accountant and (iii) describe the responsibilities of the accountant and the responsibilities of management (i.e. who audits, prepares or reviews the issuer’s financial statements, etc.). The information shall include the accountant’s phone number and email address and a description of the accountant’s licensing and qualifications to perform such duties on behalf of the issuer.

The issuer has not retained an accountant or auditor, however is in the process of doing so.

5. Public Relations Consultant(s)

The issuer does not receive consulting concerning public relations.

6. Investor Relations Consultant

The issuer does not receive investor relations consulting.

7. Any other advisor(s) that assisted, advised, prepared or provided information with respect to this disclosure statement - the information shall include the telephone number and email address of each advisor.

There are no other advisor(s) that assisted, advised, prepared or provided information with respect to this disclosure statement.

**Part D Financial Information**

**Item XV: Financial information for the issuer’s most recent fiscal period**

Balance Sheet;
Statement of Income;
Statement of Cash Flows;
Statement of changes in Stockholders’ Equity;
Financial Notes;
Audit Letter, if Audited

(Please see attachment)
Item XVI: Similar financial information for such part of the two preceding fiscal years as the issuer or its predecessor has been in existence

(Please see attachment)

Item XVII: Management's Discussion and Analysis or Plan of Operation

A. Plan of Operation

Enzyme Environmental Solutions, Incorporated produces a unique multi-enzyme solution used in a wide variety of special purpose products. The Company manufactures the enzyme products solution based on its proprietary formulas. The primary markets for the Company's products include: Retail, Agricultural, and Industrial. Enzyme use is standard in many industries such as cleaning, health, and manufacturing and as dietary supplements for both humans and animals. Enzymes act as a catalyst to accelerate the naturally occurring processes within nature. Enzyme Environmental Solutions uses no chemicals or hazardous materials to manufacture these enzymes, as all ingredients are environmentally friendly. The enzyme solution can be used to eliminate odor and organic matter - including blood stains - to clean carpets and counter tops, remove wall paper, and as a cleaner/degreaser. The wide breadth of products provided is the result of extensive research and development efforts. Over the last several years, the Company has expanded its product offering from four primary products to thirty-six distinct products. The Company continues to be focused on new markets and new product offerings.

B. Management's Discussion and Analysis of Financial Condition and Results of Operations

The company is a developmental stage company and does not have previous history of revenues so the forward projections are positive. The Company manufactures the enzyme products solution based on its proprietary formulas. The primary markets for the Company's products include: Retail, Agricultural, and Industrial. Enzyme use is standard in many industries such as cleaning, health, and manufacturing and as dietary supplements for both humans and animals.

2. Interim Periods. Provide a comparable discussion that will enable the reader to assess material changes in financial condition and results of operations since the end of the last fiscal year and for the comparable interim period in the preceding year.

This item does not apply

C. Off-Balance Sheet Arrangements

This item does not apply

Part E Exhibits

The following exhibits must be either described in or attached to the disclosure statement:
Item XIX Articles of Incorporation and Bylaws

Articles of Incorporation and By Laws on file with the corporation

Item XX: Issuer's Certifications

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles, but having the same responsibilities). The certifications shall follow the format below: I, [identify the certifying individual], certify that:

1. I have reviewed this [specify either annual or quarterly disclosure statement] of [identify issuer];

2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and

3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

Date:

[Signature]

Jared Hochstedler CEO
<table>
<thead>
<tr>
<th>Ordinary Income/Expense</th>
<th>Jan-Mar. 31</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sales</td>
<td>625,632.28</td>
</tr>
<tr>
<td>Cost of Sales</td>
<td>506,661.00</td>
</tr>
<tr>
<td>Gross Profit</td>
<td>118,971.00</td>
</tr>
<tr>
<td>Operating Expense</td>
<td>156,430.00</td>
</tr>
<tr>
<td>Net Loss</td>
<td>-37,458.00</td>
</tr>
<tr>
<td>Net Income</td>
<td>-37,459</td>
</tr>
<tr>
<td>Assets</td>
<td></td>
</tr>
<tr>
<td>--------------------------------------------</td>
<td>-------</td>
</tr>
<tr>
<td>Current Assets</td>
<td></td>
</tr>
<tr>
<td>First Source Bank</td>
<td>95,678.00</td>
</tr>
<tr>
<td>Accounts Receivable</td>
<td>25,987.00</td>
</tr>
<tr>
<td>Raw Material Inventory</td>
<td>182,657.00</td>
</tr>
<tr>
<td>Work in Process Inventory</td>
<td>11,165.00</td>
</tr>
<tr>
<td>Finished Goods Inventory</td>
<td>23,156.00</td>
</tr>
<tr>
<td><strong>Total Current Assets</strong></td>
<td><strong>338,643.00</strong></td>
</tr>
<tr>
<td>Property and Equipment</td>
<td></td>
</tr>
<tr>
<td>Furniture and Fixtures</td>
<td>5,275.00</td>
</tr>
<tr>
<td>Equipment</td>
<td>81,797.00</td>
</tr>
<tr>
<td><strong>Other Assets</strong></td>
<td><strong>87,072.00</strong></td>
</tr>
<tr>
<td>Goodwill</td>
<td>657,521.00</td>
</tr>
<tr>
<td>Formulas</td>
<td>567,251.00</td>
</tr>
<tr>
<td><strong>Total Liabilities</strong></td>
<td><strong>1,224,772.00</strong></td>
</tr>
</tbody>
</table>

| Liabilities and Shareholders' Equity       |       |
| Current Liabilities                        |       |
| Accrued officer salary                     | 775,000.00 |
| Loan from shareholder                      | 121,908.00 |
| Payable to Consultants                     | 1,450,000.00 |
| Accounts Payable                           | 12,575.00 |
| **Total Liabilities**                      | **2,359,483.00** |